Research

*January 2024* A premarket approval (PMA) application regarding the addition of tumor-treating fields (TTFields) to standard-of-care (SOC) therapies in patients with non­–small cell lung cancer (NSCLC) after disease progression on or following platinum-based treatment has been accepted for filing by the FDA.1 The PMA was supported by data from the phase…

*January 2024* Treatment with patritumab deruxtecan (HER3-DXd) in patients with locally advanced or metastatic, EGFR-mutated non–small cell lung cancer (NSCLC) resulted in clinically meaningful efficacy and long-lasting responses in those who progressed following EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy, according to data from the phase 2 HERTHENA-Lung01 study…

*January 2024* While the standard-of-care recommendations can vary depending on the individual patient, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib (Tagrisso) have played a pivotal role in the treatment of patients with EGFR-mutated lung cancer in recent years. Osimertinib tends to be the preferred first-line treatment for most patients who harbor…

*December 2023* Introduction NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports showed transformed SCLC from EGFR-mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses showed TP53 and RB1 loss of function increase the risk of SCLC transformation. Little has been…

*December 2023* The FDA has accepted and granted priority review to the biologics license application (BLA) seeking the approval of the HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who previously received at least 2…

*December 2023* Note: Amivantamab and Lazertinib may soon receive approval as a first-line treatment for EGFR+ lung cancer. A supplemental biologics license application and new drug application seeking the approval of amivantamab-vmjw (Rybrevant) plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic non–small cell lung…

*December 2023* Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is often diagnosed at an advanced stage. About half the time, it has already spread around the body and has reached stage 4. The standard treatment for most patients with metastatic NSCLC is systemic therapy (drugs that spread throughout…

*November 2023* Note: Allosteric inhibitors are an exciting new possibility to treat osimertinib resistance but are still in preclinical stage of development. Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation…